AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06522893 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Percutaneous neuromodulation
Description: Percutaneous neuromodulation therapy involves inserting several fine needle electrodes 2 cm to 5 cm deep into the skin to target the muscle and surrounding soft tissues. A low-voltage electric current is then passed through these needles, which is hypothesized to improve muscle function by altering the pain signals traveling from the painful muscle to the brain, enhance blood flow to the painful area to promote healing, reduce inflammation and soreness, and increase muscle endurance, strength, and balance.
Study NCT06522893 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous neuromodulation
Description: Percutaneous neuromodulation therapy involves inserting several fine needle electrodes 2 cm to 5 cm deep into the skin to target the muscle and surrounding soft tissues. A low-voltage electric current is then passed through these needles, which is hypothesized to improve muscle function by altering the pain signals traveling from the painful muscle to the brain, enhance blood flow to the painful area to promote healing, reduce inflammation and soreness, and increase muscle endurance, strength, and balance.
Study NCT05599282 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amino Acid Supplement
Description: Four capsules of Amino Acid Supplement will be taken once a day for 90 days.
Study NCT05599282 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Four capsules of Placebo will be taken once a day for 90 days.
Study NCT06238934 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bone marrow aspirate matrix
Description: Bone marrow aspirate \* Hyaluronic acid
Study NCT06238934 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Bone marrow aspirate
Description: Bone marrow aspirate
Study NCT06238934 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hyaluronic acid
Description: Hyaluronic acid
Study NCT05636046 — intervention group
Intervention type: PROCEDURE
Intervention: transseptal catheterization
Description: puncture of interatrial septum at the level of fossa ovalis, using transseptal needle.
Study NCT04751604 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nicotinamide
Description: Daily oral administration of 1,000 mg nicotinamide \[1x 500-mg conventional nicotinamide tablet and 1x 500-mg tablet with controlled-ileocolonic-release nicotinamide (CICR-NAM)\] for 4 weeks
Study NCT04751604 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Daily oral administration of 2 matching placebo tablets for 4 weeks
Study NCT06086158 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Nordic Reverse Protocol
Description: The participant begins on their knees, with the trunk upright and fully aligned. At this moment, the soccer player slowly leans back, maintaining the starting position by means of a controlled flexion of the knees. This fall is executed at the lowest speed possible to maximize muscle load in the eccentric phase and reach the point of maximum flexion.
Study NCT05327842 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: New training simulator
Description: Participants receive training with new simulator
Study NCT05327842 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Traditional simulator
Description: Participants receive traditional training
Study NCT04880083 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Commercially Available Starter Infant Formula
Description: Study formula is provided in powder form and will be administered orally, ad libitum, via an infant feeding bottle and the volume of formula offered to the infant will be guided by the recommended feeding table for the age group or by physician recommendation. The amount consumed by the infant will vary by each infant's weight and appetite.
Study NCT05135585 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Blood sample collection
Description: Blood sample collection at 1 month and 6 months after vaccination
Study NCT05135585 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Questionnaires
Description: data collection (health data, vaccination data, etc.)
Study NCT05725967 — intervention group
Intervention type: DEVICE
Intervention: Argon Plasma Coagulation, Gastroplasty with Endoscopic Myotomy, Bariatric Endoscopic Antral Myotomy, Pylorus Sparing Antral Myotomy
Description: Electrosurgical interventions for obesity. Use of electrosurgical devices, such as electrocautery for the primary treatment of obesity or obesity related complications.
Study NCT05725967 — intervention group
Intervention type: DEVICE
Intervention: Aspiration Therapy
Description: Placement of an aspiration therapy device for the treatment of obesity.
Study NCT05348993 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G03-52-01
Description: G03-52-01 administered intramuscularly
Study NCT05348993 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: G03-52-01
Description: G03-52-01 administered intramuscularly
Study NCT05348993 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: placebo
Study NCT05348993 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo
Study NCT05898672 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rosuvastatin
Description: Single oral dose of rosuvastatin tablets
Study NCT05898672 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: Single oral dose of rosuvastatin tablets
Study NCT05898672 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nirmatrelvir/ritonavir
Description: Twice daily oral doses of nirmatrelvir/ritonavir tablets
Study NCT04984083 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: vitamin k
Description: patients will take vitamin k 10 mg/ml once daily orally or IM between four and 96 hours before elective cesarean section
Study NCT06013670 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopy+NSBBs
Description: Endoscopic treatment+NSBBs group: After admission, carvedilol 6.25mg qd p.o. was administered to lower portal vein pressure. After one week without any adverse reactions, add the dosage to 12.5mg qd, maintained for a long time, with close monitoring of blood pressure and pulse (morning and evening monitoring) during dosing and later use, to maintain systolic blood pressure>90mmHg and heart rate>55bpm. Otherwise, dosage reduction or even discontinuation of medication is necessary. Endoscopic treatment adopts sequential treatment, with an interval of four weeks, until the varicose vein becomes mild or disappears.
Study NCT06013670 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transjugular intrahepatic portosystemic shunt
Description: TIPS group: All TIPS procedures are completed by a professional liver disease intervention treatment team.
Study NCT05490329 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tough Talks COVID
Description: Intervention participants will download the TT-C app from the iOS or Google Play store and complete the intervention within one month.
Study NCT04984720 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Smartphone based digital application
Description: Smartphone Based Digital Application to Track Migraine, Offer Pill Reminders for Medication Adherence and Community Blog
Study NCT04984720 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Smartphone based digital application
Description: Smartphone Based Digital Application to Track Migraine, Offer Pill Reminders for Medication Adherence and Community Blog
Study NCT04933045 — intervention group
Intervention type: DEVICE
Intervention: Arthrex InternalBrace
Description: Placement of Arthrex InternalBrace for anatomic distal tibiofibular ligament augmentation to stabilize the ankle syndesmosis during surgery.
Study NCT05121259 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ExerciseGuide Intervention Group
Description: The single group which will be given access to the eight-week ExerciseGuide UK website containing a tailored physical activity programme and supportive and educational resources.
Study NCT06328868 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intermittent Oral-esophageal Tube Feeding
Description: The specific procedure was as follows: the infant was placed in a semi-recumbent or sitting position with the head fixed. Before each feeding, the infant's oral and nasal secretions were to be cleared. An intermittent oro-esophageal tube was appropriately lubricated with water on the head part. The professional medical staff held the tube and slowly inserted it through one side of the mouth into the upper part of the esophagus. The depth of insertion depended on the patient's age and height. After each feeding, the tube was immediately removed, and the patient was held upright for at least 30 minutes in case of reflux.
Study NCT06328868 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Nasogastric Tube Feeding
Description: Nasogastric Tube Feeding were used for feeding to provide nutritional support. Each feeding was administered by a nurse using the infant's mother's breast milk through the tube. The amount of each feeding varied from 20 to 100 ml depending on the age of the infant, with feedings given every 2 to 3 hours, approximately 10 times per day. The duration of each feeding procedure ranged from 10 to 20 minutes. The total daily intake ranged from 200 to 1000 ml. Each tube was kept indwelling for 5 to 7 days. When the tube needed to be replaced, it was removed after the last feeding of a day and a new tube was to be inserted through the other nostril on the following morning to continue the nutritional support.
Study NCT06328868 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: comprehensive rehabilitation therapy
Description: Both groups were given comprehensive rehabilitation therapy. The main intervention measures included: 1) non-invasive ventilator treatment, generally at least once every night and typically not exceeding continuous daily usage.; 2) attention to feeding and sleeping positions, with a recommended sleeping position of lateral recumbent and the head of the bed raised by 20-30°; 3) swallowing function training, such as tongue muscle stretching training, assisted anterior jaw protrusion training, lemon ice stimulation to the soft palate, pharyngeal wall, etc., generally 5 days per week, twice per day, 5-20 minutes each time; 4) pulmonary ultrashort wave therapy, generally at least 2-3 times a week, and not more than once a day; 5) physical therapy, such as intensive training for gross motor functions including lifting the head, turning over, sitting, crawling, standing, etc., generally 3-5 days per week, 1-2 times per day, 5-20 min each time.
Study NCT06328868 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: comprehensive rehabilitation therapy
Description: Both groups were given comprehensive rehabilitation therapy. The main intervention measures included: 1) non-invasive ventilator treatment, generally at least once every night and typically not exceeding continuous daily usage.; 2) attention to feeding and sleeping positions, with a recommended sleeping position of lateral recumbent and the head of the bed raised by 20-30°; 3) swallowing function training, such as tongue muscle stretching training, assisted anterior jaw protrusion training, lemon ice stimulation to the soft palate, pharyngeal wall, etc., generally 5 days per week, twice per day, 5-20 minutes each time; 4) pulmonary ultrashort wave therapy, generally at least 2-3 times a week, and not more than once a day; 5) physical therapy, such as intensive training for gross motor functions including lifting the head, turning over, sitting, crawling, standing, etc., generally 3-5 days per week, 1-2 times per day, 5-20 min each time.
Study NCT04838860 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Siltuximab
Description: Participants will receive intravenous (IV) infusion of siltuximab 22 mg/kg over 2 hours every 3 weeks, then possibly dose escalating to 33 mg/kg IV over 3 hours +/- 44 mg/kg IV over 4 hours every 3 weeks if clinically indicated in the absence of dose-limiting toxicity.
Study NCT04788524 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Computer Task Manipulation
Description: Participants will complete computer tasks.
Study NCT05666999 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: FibDex®
Description: To monitor and compare the clinical performance and safety of the CE marked wound care product (FibDex®) when used according to its intended use for patients or individuals with split thickness skin graft (STSG) donor site wounds.
Study NCT05666999 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Suprathel
Description: To monitor and compare the clinical performance and safety of the CE marked wound care product (FibDex®) when used according to its intended use for patients or individuals with split thickness skin graft (STSG) donor site wounds.
Study NCT05666999 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Aquacel Foam
Description: To monitor and compare the clinical performance and safety of the CE marked wound care product (FibDex®) when used according to its intended use for patients or individuals with split thickness skin graft (STSG) donor site wounds.
Study NCT05212298 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: The gel contains a mixture of glucose and maltodextrin
Description: The gel contains a mixture of glucose and maltodextrin - a complex carbohydrate - along with fat and a trace of protein.
Study NCT05212298 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Herbal compound low-dose
Description: The total amount of herbal compound capsules is 557 mg.
Study NCT05279924 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prophylaxis with Emicizumab
Description: Prophylaxis with Emicizumab in Ivoirian boys with severe hemophilia A
Study NCT04992208 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Experimental Group
Description: SARS-CoV-2 Inactivated Vaccine 600SU inactivated virus in 0·5 mL of aluminium hydroxide solution per injection
Study NCT05212298 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Herbal compound high-dose
Description: The total amount of herbal compound capsules is 1114 mg.
Study NCT06592261 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin regular, 2.0-3.2 mU/m2/min (euinsulinemia)
Description: Insulin infusion to recapitulate euinsulinemia (normal basal insulin)
Study NCT06592261 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin regular, 32 mU/m2/min (hyperinsulinemia)
Description: Insulin infusion to induce hyperinsulinemia for assessment of insulin sensitivity
Study NCT06592261 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Octreotide Acetate, 6-45 ng/kg/min
Description: Suppression of endogenous insulin secretion
Study NCT06592261 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dextrose 20 % in Water
Description: Production of steady-state plasma glucose (SSPG) reflective of insulin sensitivity at hyperinsulinemia
Study NCT06592261 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glucagon, 0-0.5 ng/kg/min
Description: Replacement of endogenous glucagon suppressed by octreotide. (Use is optional at the PI's discretion.)
Study NCT05237791 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magnesium sulfate
Description: magnesium sulphate 50mg/kg (loading dose for 10 minutes), 15mg/kg/hr (continuous infusion)
Study NCT05237791 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: normal saline 100ml (loading dose for 10 minutes), 15mg/kg/hr (continuous infusion)
Study NCT05138497 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HILIT
Description: A total of 92 men and women 65 years old, distributed in an experimental group that will receive a 12-week of HILIT program (n = 46); and a control group (n = 46) that will only receive general recommendations on the benefits of physical exercise. The variables will be measured for both groups with the same validated tools and the same researcher to avoid information biases and differential incorrect classification.
Study NCT06040125 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Supervised Circuit Training
Description: 16-week, multicomponent exercise intervention comprised of sessions supervised by certified exercise oncology trainer and home-based, self-directed aerobic exercises. Stationary bike and accelerometer (activity/heart rate monitor) will be provided.
Study NCT05686746 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baricitinib 4 MG
Description: 4 mg oral daily
Study NCT05686746 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baricitinib 2 MG
Description: 2 mg oral daily
Study NCT05686746 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MMF
Description: 1000 mg oral daily
Study NCT06139432 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active tDCS
Description: * Anode opposite the left dorsolateral prefrontal cortex (between F3 and FP1 according to the 10-20 international placement system).~* Cathode opposite the left temporoparietal junction (between T3 and P3).~* The stimulation level is 2mA for 20 minutes.~* Sessions are held twice daily on working days (with a minimum of 3 hours between sessions).~Twenty sessions will be carried out, two sessions per consecutive working day.
Study NCT06139432 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham tDCS
Description: * Anode opposite the left dorsolateral prefrontal cortex (between F3 and FP1 according to the 10-20 international placement system).~* Cathode opposite the left temporoparietal junction (between T3 and P3).~* Effective stimulation is delivered for 30 seconds (stimulation level is 2 mA), after which effective stimulation stops. The entire session is 20 minutes, with 19 minutes and 30 seconds without stimulation.~* Sessions are held twice daily on working days (with a minimum of 3 hours between sessions).~Twenty sessions will be carried out, two sessions per consecutive working day.
Study NCT06075511 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Body Composition Scan
Description: Measure of body fat percentage, skeletal muscle mass, body water, and visceral fat.
Study NCT06075511 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Mixed meal testing
Description: Subjects will consume 6 ml/kg body weight of Boost, up to maximum of 360 ml, within 5 min
Study NCT06075511 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Quality of Life
Description: Subject will complete Quality of Life Questionnaire
Study NCT06456268 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VibraCool mechanical stimulation and neuromodulatory therapeutic device
Description: Multiple studies have shown that vibration sources applied to muscles prior to exercise reduced soreness and lactate dehydrogenase production, and increased range of motion at 48 and 72 hours. Acute pain results from fast A nerves transmitting nociceptive information to the dorsal column, where the substantia gelatinosa's interneurons prioritize competing A mechanoreceptor and C-fibers to slow pain transmission. One study observed that stimulation of A mechanoreceptors shut the gate on pain transmission, an inhibitory mechanism known as gate control. Multiple physical methodologies leverage gate control physiology for pain relief, such as vibratory massage therapy and electrical stimulation to varying degrees. However, the use of vibratory massage to improve pain control and reduce opioid use following ACLR has not been well studied, and to our knowledge there are no randomized control trials (RCTs) evaluating the use of this modality compared to standard ice or cryocompression.
Study NCT06456268 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cryocompression (Game Ready, Bregs) device
Description: Cryotherapy has also been used as an adjunctive post-operative therapy to reduce pain and inflammation following anterior cruciate ligament reconstruction (ACLR). It has been shown to decrease local metabolism, resulting in reduced pain and inflammation. Multiple studies have shown the benefits of using cryotherapy after ACLR, and more recently dynamic intermittent compression has been shown to improve circulation while reducing the risk of skin necrosis associated with static permanent compression. A recent meta-analysis including ten RCTs found significant reductions in post-operative VAS pain scores and breakthrough opioid consumption when using cryotherapy, such as Game Ready or Breggs ice therapy, following ACLR.
Study NCT06456268 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard ice packs
Description: Cold also provides peripheral gate-control relief via small, slow C-Fibers that transmit low level pain. In addition to local pain relief, intense cold can raise the A pain threshold distant to the location. The mechanism has been called descending or diffuse noxious inhibitory relief, or more recently conditioned pain modulation (CPM). Injections, aches, and infiltration of local anesthesia and dermal fillers are relieved by applying cold. For acute injury, near freezing cold relieves pain by suppressing the local metabolic production of inflammation and concomitant tissue ischemia from hypoxia due to the increased metabolic rate.
Study NCT04985903 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Clinician Communication Intervention
Description: The focus of the communication program is to help clinicians increase their use of the 5 A's by improving knowledge, self-efficacy, outcome expectations, and communication skills. Training modules include didactic information with video clips of sample conversations showing specific communication skills, feedback on clinician's usage of the 5A's, and audio clips from their Pre-Intervention recorded conversations.
Study NCT04985903 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 5A's lecture
Description: a lecture on general information about smoking cessation for pregnant patients and smoking cessation counseling.